[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100402434":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":24,"centralContacts":28,"locations":36,"responsibleParty":51,"collaborators":20,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":20,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":20,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":20,"overallStatus":39,"whyStopped":20,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Wright State University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"4% Imipramine Cream on UVB-Treated Areas","EXPERIMENTAL","* 2g of 4% imipramine cream will be applied to the UVB-treated areas on volar forearm and back.\n* 2g of base cream will be applied to the UVB-treated areas on volar forearm and back.\n* No cream will be applied to a UVB-treated area on the back",[13,14],"Drug: 4% Imipramine Cream","Drug: Base Cream",[16,21],{"type":17,"name":18,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","4% Imipramine Cream",[9],null,{"type":17,"name":22,"description":22,"armGroupLabels":23,"otherNames":20},"Base Cream",[9],[25],{"name":26,"affiliation":5,"role":27},"Jeffrey B Travers, MD, PhD","PRINCIPAL_INVESTIGATOR",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":20,"email":33},"Manager Clinical Research Operations","CONTACT","937-245-7500","pturesearch@wrightstatephysicians.org",{"name":35,"role":31,"phone":32,"phoneExt":20,"email":33},"Regulatory Specialist",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":20},"Wright State Physicians","RECRUITING","Fairborn","Ohio","45324","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-84.01938,39.82089,{"lat":49,"lon":48},{"type":52,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100402434","phase-1-testing-use-of-topical-imipramine-in-reducing-ultraviolet-b-induced-microvesicle-particle-release-in-photosensitive-subjects-100402434",false,"NCT04520217","Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects","Pilot Studies Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects","Inclusion Criteria:\n\n* Female and Male adult subjects age 18 to 50\n* Must be able to give informed consent\n* Have access to stable transportation\n* All skin types on Fitzpatrick Scale (Type I-VI)\n* Self-Identified photosensitivity\n* Able to provide medical history and list of medications-control subjects will not be allowed to be taking a medication that is known to be photosensitizer.\n\nExclusion Criteria:\n\n* Underlying diseases that could affect wound healing (e.g., uncontrolled diabetes mellitus)\n* Taking medications that are known photosensitizers (e.g., doxycycline) or anti-inflammatories (e.g., NSAIDS \\[except for low-dose aspirin\\] or steroids)\n* Utilizing imipramine or any other tricyclic antidepressant (oral or cream)\n* Utilizing topical anti-inflammatory or systemic agents (e.g., prednisone)\n* Large tattoos in the designated testing areas\n* Tanning bed use within last 3 months\n* Photodynamic Therapy or UVB treatments in past 3 months\n* Female Subjects: pregnant or nursing\n* History of abnormal scarring (i.e., keloids)",true,"ALL","18 Years","50 Years",{"count":65,"type":66},40,"ESTIMATED","INTERVENTIONAL",[69],"PHASE1","The purpose of this study is three-fold. First, researchers will assess whether subjects who have clinically abnormal reactions to sunlight (photosensitivity) have increased levels of microvesicle particles (MVP) following ultraviolet B (UVB) treatment to localized area of skin. Second, researchers will assess if topical application of the medicine imipramine will block UVB-induced MVP release. Third, researchers will assess if the topical cream will block UVB-induced increased erythema reactions (reddening of the skin).",[72,73],"Photosensitivity","Microvesicle Particle","2025-01-24",{"date":76,"type":77},"2025-01-27","ACTUAL",{"date":79,"type":77},"2022-06-06",{"date":81,"type":66},"2026-12-01",{"name":5,"class":6},1]